Skip to main content
About
Executive Team
Board of Directors
How We Operate
Quality
Capabilities
Locations
News
Products
Contract Manufacturing
Investors
Careers
Careers
Benefits
Available Positions
Application
Contact
Contact Us
Locations
News
Overview
News
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Investment Calculator
Analyst Coverage
Financials
Quarterly Results
Annual Reports
SEC Filings
Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Information Request Form
Investor Email Alerts
Investor Contacts
Site Search
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2008
12/17/2020
ANI Pharmaceuticals Announces Approval and Launch of Aminocaproic Acid Tablets
11/05/2020
ANI Pharmaceuticals Reports Third Quarter 2020 Results
10/29/2020
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter 2020 Financial Results
Download
PDF format download (opens in new window)
09/10/2020
ANI Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08/06/2020
ANI Pharmaceuticals Reports Second Quarter 2020 Results
Download
PDF format download (opens in new window)
08/06/2020
ANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio “Tony” Pera to Board of Directors
08/03/2020
ANI Pharmaceuticals Names Nikhil Lalwani as President and Chief Executive Officer
07/30/2020
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter 2020 Financial Results
07/06/2020
ANI Pharmaceuticals Announces Acquisition of Fluconazole Tablets
06/30/2020
ANI Pharmaceuticals Announces Launch of Mexiletine Hydrochloride Capsules
06/01/2020
ANI Pharmaceuticals Provides Update on Recent Regulatory Filing
05/07/2020
ANI Pharmaceuticals Reports First Quarter 2020 Results
Download
PDF format download (opens in new window)
Earnings Release Tables
PDF
PDF format download (opens in new window)
04/29/2020
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2020 Financial Results
04/28/2020
ANI Receives Refusal to File Letter from FDA for Cortrophin® Gel
04/14/2020
ANI Announces Upcoming Departure of CEO
04/13/2020
ANI Announces FDA Acceptance of Supplemental Filing for Cortrophin® Gel 80 U/mL FDA Sets Prescription Drug User Fee Act (PDUFA) Goal Date of July 23, 2020
04/02/2020
ANI Pharmaceuticals Announces Launch of Omega-3-Acid Ethyl Esters Capsules USP
04/01/2020
ANI Announces Launch of Polyethylene Glycol 3350, 17g/Packet
03/24/2020
ANI Pharmaceuticals Announces the Filing of a Prior Approval Supplement for Purified Cortrophin® Gel 80 U/mL
03/17/2020
ANI Pharmaceuticals Announces FDA Approval of Memantine Hydrochloride Extended-Release Capsules
02/27/2020
ANI Pharmaceuticals Reports Fourth Quarter 2019 Results
Download
PDF format download (opens in new window)
Earnings Release Tables
PDF
PDF format download (opens in new window)
02/25/2020
ANI Announces Launch of Tolterodine Extended-Release Capsules
02/20/2020
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2019 Financial Results
02/12/2020
ANI Announces Launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL
01/16/2020
ANI Pharmaceuticals Announces FDA Approval of Potassium Citrate Extended-Release Tablets USP
01/14/2020
ANI Announces Launch of Paliperidone Extended-Release Tablets
01/09/2020
ANI Pharmaceuticals Announces Acquisition of Commercial and Pipeline Generic Products from Amerigen Pharmaceuticals, Ltd.